Edition:
India

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

33.75USD
22 Jun 2018
Change (% chg)

$-0.50 (-1.46%)
Prev Close
$34.25
Open
$34.35
Day's High
$34.35
Day's Low
$32.92
Volume
340,013
Avg. Vol
226,106
52-wk High
$51.00
52-wk Low
$26.98

Chart for

About

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $1,474.48
Shares Outstanding(Mil.): 40.34
Dividend: --
Yield (%): --

Financials

  PCRX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.71 -- --
ROI: -16.47 14.84 14.38
ROE: -26.87 16.34 16.08

BRIEF-Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11

* PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

28 Feb 2018

BRIEF-Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​

* PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA

16 Feb 2018

BRIEF-Pacira Pharmaceuticals Says FDA Advisory Committee To Review SNDA For Exparel

* PACIRA PHARMACEUTICALS STOCK TRADING HALTED; FDA ADVISORY COMMITTEE TO REVIEW SNDA FOR EXPAREL® AS A NERVE BLOCK FOR REGIONAL ANALGESIA Source text for Eikon: Further company coverage:

15 Feb 2018

BRIEF-Pacira Pharma says FDA Posts Briefing Documents For Advisory Meeting Reviewing SNDA For Exparel

* PACIRA PHARMACEUTICALS INC - FDA POSTS BRIEFING DOCUMENTS FOR ADVISORY MEETING REVIEWING SNDA FOR EXPAREL AS A NERVE BLOCK FOR REGIONAL ANALGESIA

13 Feb 2018

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

04 Jan 2018

Competitors

Earnings vs. Estimates